Attached files
| file | filename |
|---|---|
| 10-K - 10-K - HUMAN GENOME SCIENCES INC | w81670e10vk.htm |
| EX-10.2 - EX-10.2 - HUMAN GENOME SCIENCES INC | w81670exv10w2.htm |
| EX-32.2 - EX-32.2 - HUMAN GENOME SCIENCES INC | w81670exv32w2.htm |
| EX-23.1 - EX-23.1 - HUMAN GENOME SCIENCES INC | w81670exv23w1.htm |
| EX-31.1 - EX-31.1 - HUMAN GENOME SCIENCES INC | w81670exv31w1.htm |
| EX-32.1 - EX-32.1 - HUMAN GENOME SCIENCES INC | w81670exv32w1.htm |
| EX-10.3 - EX-10.3 - HUMAN GENOME SCIENCES INC | w81670exv10w3.htm |
| EX-31.2 - EX-31.2 - HUMAN GENOME SCIENCES INC | w81670exv31w2.htm |
| EX-21.1 - EX-21.1 - HUMAN GENOME SCIENCES INC | w81670exv21w1.htm |
EXHIBIT 12.1
| Ratio of Earnings to Fixed Charges | ||||||||||||||||||||
| (dollars in thousands, except ratio data) | ||||||||||||||||||||
| Year ended December 31, | ||||||||||||||||||||
| 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||
Earnings (Loss): |
||||||||||||||||||||
Earnings (loss) before provision for
income taxes |
$ | (233,231 | ) | $ | 4,385 | $ | (268,891 | ) | $ | (284,371 | ) | $ | (264,087 | ) | ||||||
Fixed Charges |
78,108 | 77,780 | 82,930 | 80,927 | 59,505 | |||||||||||||||
Total Earnings (Loss) |
$ | (155,123 | ) | $ | 82,165 | $ | (185,961 | ) | $ | (203,444 | ) | $ | (204,582 | ) | ||||||
Fixed Charges: |
||||||||||||||||||||
Interest expense on indebtedness
(including amortization of debt
expense and discount) |
$ | 59,500 | $ | 58,424 | $ | 62,912 | $ | 60,716 | $ | 39,606 | ||||||||||
Interest expense on portion of rent
expense representative of interest |
18,608 | 19,356 | 20,018 | 20,211 | 19,899 | |||||||||||||||
Total Fixed Charges |
$ | 78,108 | $ | 77,780 | $ | 82,930 | $ | 80,927 | $ | 59,505 | ||||||||||
Ratio of Earnings to Fixed Charges |
— | 1.06 | — | — | — | |||||||||||||||
Coverage deficiency (1)(2)(3) |
$ | (233,231 | ) | $ | — | $ | (268,891 | ) | $ | (284,371 | ) | $ | (264,087 | ) | ||||||
| (1) | The Company’s Ratio of Earnings to Fixed Charges for 2009 includes a gain on extinguishment debt of $38,873, a gain on sale of an equity investment of $5,259 and reflects revenues received in connection with the delivery of raxibacumab to the Strategic National Stockpile. These amounts should not be considered indicative of the Company’s future performance. | |
| (2) | The Company’s Coverage deficiency for 2008 includes a gain on the sale of an equity investment of $32,518 partially offset by a charge for impaired investment of $6,284. | |
| (3) | The Company’s Coverage deficiency for 2006 includes charges for facility-related exit charges of $29,510 partially offset by a gain on the sale of an equity investment of $14,759. |